抗肿瘤坏死因子治疗期间下行疼痛调控的变化:类风湿关节炎与脊柱关节炎的前瞻性研究
研究纳入100例(50例类风湿关节炎、50例脊柱关节炎)未用过生物制剂或靶向合成改善病情抗风湿药且开始肿瘤坏死因子抑制剂治疗的活动性疾病患者,随访六个月。热痛阈值无显著变化,条件性疼痛调控效应显著改善;无显著疼痛者及达到缓解或低疾病活动度者的条件性疼痛调控效应更高。
要点
- 活动性类风湿关节炎或脊柱关节炎患者启动肿瘤坏死因子抑制剂后,条件性疼痛调控效应在六个月随访中显著改善。
- 热痛阈值在随访期间无显著变化。
- 无显著疼痛及达到缓解或低疾病活动度者,随访结束时条件性疼痛调控效应更高。
核心结论
- 在活动性炎症性风湿病中,肿瘤坏死因子抑制剂治疗后受损的下行疼痛调控改善,而热痛阈值未改善,提示肿瘤坏死因子抑制剂可能对中枢疼痛调控有作用。
研究设计与样本
- 风湿病疼痛抑制下行通路研究为前瞻性研究,纳入100例活动性疾病患者(50例类风湿关节炎和50例脊柱关节炎),均为未使用过生物制剂或靶向合成改善病情抗风湿药且开始肿瘤坏死因子抑制剂治疗者,随访六个月,进行临床、心理和疼痛评估以及定量感觉测试(热痛阈值、冷痛阈值和条件性疼痛调控)。
主要发现
- 100例患者中59例为女性,平均±标准差年龄45.8±14.6岁,74例完成六个月随访。
- 随访期间热痛阈值无显著变化。
- 条件性疼痛调控效应在随访期间显著改善(基线平均±标准差0.25±2.57°C,六个月时2.96±2.50°C;P<0.001)。
- 随访结束时,无显著疼痛患者(简明疼痛评估量表≤3/10)的平均条件性疼痛调控效应显著高于持续疼痛患者(>3/10)(平均±标准差3.25±2.68°C vs 2.47±2.11°C;P=0.04)。
- 随访结束时,达到缓解或低疾病活动度患者的平均条件性疼痛调控效应显著高于活动性风湿病患者(平均±标准差3.31±2.68°C vs 2.18±1.87°C;P=0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of biologic disease-modifying antirheumatic drugs (bDMARDs). The objective of the Rheumatism Pain Inhibitory Descending Pathways study was to assess pain thresholds and descending pain modulation in patients with active RA or SpA following introduction of a tumor necrosis factor inhibitor (TNFi). METHODS: Patients with active disease (50 with RA and 50 with SpA) naive to bDMARDs or targeted synthetic DMARDs and starting a TNFi were included. Patients were observed for six months after TNFi initiation with clinical, psychological, and pain assessment. At all visits, participants underwent quantitative sensory testing with heat and cold pain thresholds and descending inhibition by conditioned pain modulation (CPM). Descending pain control (CPM effect) was assessed as the change in heat pain threshold (°C) following a conditioning stimulus. RESULTS: Of the 100 patients (59 women, mean ± SD age 45.8 ± 14.6 years), 74 completed the six-month follow-up. Thermal pain thresholds did not significantly change during follow-up. CPM effect improved significantly during follow-up (mean ± SD 0.25 ±2.57°C at baseline and 2.96 ± 2.50°C at six months; P < 0.001). At the end of follow-up, the mean CPM effect was significantly higher in patients without significant pain compared with patients with persistent pain (>3 of 10 on the Brief Pain Inventory) (mean ± SD 3.25 ± 2.68°C vs 2.47 ± 2.11°C; P = 0.04) and in patients achieving remission or low disease activity compared with patients with active rheumatism (mean ± SD 3.31 ± 2.68°C vs 2.18 ± 1.87°C; P = 0.01). CONCLUSION: In active inflammatory rheumatisms, impaired descending pain modulation, but not thermal pain thresholds, is improved after TNFi treatment, suggesting a possible effect of TNFi on central pain modulation.
引用
- Trouvin AP, Simunek A, Coste J, et al. Changes in Descending Pain Modulation During Anti-Tumor Necrosis Factor Therapy: A Prospective Study in Rheumatoid Arthritis and Spondyloarthritis. Arthritis Rheumatol. 2025. PMID: 39679776. doi:10.1002/art.43084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。